About Us

About Us
Paul Hallenbeck

Dr. Hallenbeck

Meet the Founder

Paul L. Hallenbeck, Ph.D.
Chief Executive Officer

Dr. Hallenbeck is the Founder, CEO, President, and Director of Seneca Therapeutics, a privately held, clinical-stage cutting edge biotechnology company focused on developing novel oncolytic immunotherapeutics for the treatment of cancer.  He earned his PhD in Microbiology at the University of Illinois and completed his Postdoctoral work at the National Institute of Health.  Dr. Hallenbeck has 25 years of biopharmaceutical research and development experience in oncology primarily focused on novel therapeutics such as gene and cell therapy, oncolytic viruses, molecularly targeted agents, and immunotherapeutics.  Paul was instrumental in the leadership and discovery of numerous therapeutics for cancer and shepherding them into and through clinical trial development.  His past roles include being on the senior management team at Novartis Pharmaceutics where he was presented with a life time achievement award.  He was also Founder, President, CSO, and Director of Neotropix, a leading oncolytic immunotherapeutic company where he won Ernst and Young’s Entrepreneur of the Year Award and Frost Sullivan’s Product Innovation of the Year Awards.   In his role as Chief Scientific Officer of Bensen Pharmaceutics, he won a Prestigious National Distinguished Expert Award.

Zachary Morris, MD PhD joins Seneca Therapeutics’ Clinical Advisory Board

Seneca Therapeutics is pleased to welcome Zachary Morris, MD, PhD, to its Clinical Advisory Board.  Dr. Morris will work closely with Dr. Paul Hallenbeck, founder and CEO of Seneca Therapeutic, Inc. as the company is on target to begin a Phase II Clinical Ready trial with its leading candidate, SVV in a combination immunotherapeutic treatment for patients with cancer.  The Phase II Ready clinical trial is set to begin in early 2020.

As a physician-scientist, Dr. Morris’ current clinical focus is on the treatment of patients with melanoma and soft tissue sarcomas. Dr. Morris’ independent translational research laboratory focuses on the mechanisms whereby radiation may enhance the response to immunotherapies.

Dr. Morris is an assistant professor and vice chair of the Department of Human Oncology at the University of Wisconsin. He is originally from Rockford, Ill., and completed his undergraduate studies at Ripon College in Ripon, Wisconsin. Dr. Morris earned two Master’s degrees (Medical Anthropology and History of Science, Medicine, and Technology) at Oxford University as a Rhodes Scholar.  He completed his MD at Harvard Medical School and earned a PhD at Harvard University in the Biological and Biomedical Sciences Program, where he successfully performed thesis research in the laboratory of Prof. Andrea McClatchey.

Dr. Morris completed a preliminary year internship in internal medicine at the University of Hawaii and then completed his residency training in radiation oncology at the University of Wisconsin Hospitals and Clinics. Under the American Board of Radiology’s Holman Pathway, he spearheaded a collaborative research project during his residency in the labs of Prof. Paul Sondel and Prof. Paul Harari.

Pennsylvania Biotechnology Center Press Release

“Entrepreneur Spotlight” Showcases Local Biotech Companies to Potential Investors

August 3, 2018: More than 100 area business leaders and biotech investors gathered on July 20 for the 4th Annual “Entrepreneur Spotlight” at the Pennsylvania Biotechnology Center in Doylestown. The Spotlight is a Shark Tank-style event showcasing companies based at the center to potential investors.

Read more.

Partnerships/Collaborations

null

Strength in numbers and stronger together. Seneca Therapeutics welcomes collaborations and partnerships that together will build an oncolytic immunotherapeutic foundation on which research and development efforts will harvest even greater discoveries in the treatment of cancer.

Seneca Therapeutics is currently collaborating with teaching hospitals, research universities and cancer centers around the world.